OPKO Health | OPK

Stock Price
455.80
Daily Change
-5.30 -1.15%
Monthly
6.30%
Yearly
-21.71%
Q3 Forecast
457.27

Peers Price Chg Day Year Date
Supermax Corporation Bhd 0.47 0 0% -31.22% Sep/04
Alcidion 0.09 0.001 1.11% 44.44% Sep/05
Ambu A/S 96.80 1.75 1.84% -24.76% Sep/05
Amplifon 15.28 0.19 1.23% -45.41% Sep/05
Apollo Hospitals Enterprise Ltd 7,804.50 -95.50 -1.21% 13.00% Sep/05
Convatec Group 239.00 0 0% 2.75% Sep/05
Diasorin 82.34 -0.22 -0.27% -18.60% Sep/05
Gulf Medical Proj 2.27 0.12 5.58% 32.75% Sep/04
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Med Life 7.48 0 0% 31.00% Sep/05
Oriola-kd 1.17 0.01 0.51% 26.92% Sep/05
OPKO Health 455.80 -5.30 -1.15% -21.71% Sep/07
Rede D'Or Sao Luiz 39.30 0.26 0.67% 17.84% Sep/05
Siemens Healthineers 47.24 0.10 0.21% -5.71% Sep/06
Sonova Holding 239.50 1.90 0.80% -19.82% Sep/05


OPKO Health Inc traded at 455.80 this Sunday September 7th, decreasing 5.30 or 1.15 percent since the previous trading session. Looking back, over the last four weeks, OPKO Health lost 6.30 percent. Over the last 12 months, its price fell by 21.71 percent. Looking ahead, we forecast OPKO Health Inc to be priced at 457.27 by the end of this quarter and at 445.98 in one year, according to Trading Economics global macro models projections and analysts expectations.

OPKO Health, Inc. is a healthcare company. Its segments include Diagnostics and Pharmaceutical. The Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP, hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.